title: Percent free prostate-specific antigen in assessing the probability of prostate cancer under optimal analytical conditions.
abstract: Although general consensus exists that percent free prostate-specific antigen (PSA) is superior to total immunoreactive PSA for prostate cancer (CaP) detection, its diagnostic performance is not yet well established. Analytical problems may account for difficulties in evaluating percent free PSA because the free PSA concentration is substantially lower than that of total PSA. The aim of the present study was to establish the diagnostic performances of the IMMULITE percent free PSA assay from Diagnostics Products Corp. under experimental conditions optimized to minimize analytical variability. Eighty-five patients with untreated primary CaP and 261 with untreated benign prostate hypertrophy (BPH) were prospectively enrolled. The Diagnostics Products IMMULITE total (Third Generation) and free PSA were measured by the same technician, using the same instrument and the same reagent batch. We calculated the post-test probability to express how the likelihood of the diagnosis of CaP changed after the percent free PSA was determined. Areas under the ROC curves of percent free PSA were better than those of total PSA in every evaluated range of total PSA. The percent free PSA could have reduced the rate of unnecessary biopsies by 47% in patients with total PSA >/=4 microg/L with only 3.8% false-negative results. The post-test probability of percent free PSA was, however, <50% in men 50-70 years of age, using cutoff points providing sensitivity from 99% to 80%. Percent free PSA is superior to total PSA in distinguishing primary CaP from BPH in patients with total PSA between 2 and 30 microg/L. In men with low total PSA, the diagnostic performance of the percent free PSA assay may be optimized by controlling methodological variability. The percent free PSA assay is effective in reducing the rate of unnecessary biopsies in men with total PSA >4 microg/L. However, the post-test probability provided by percent free PSA is relatively low in asymptomatic patients 50-70 years of age.
authors.affiliation: Centro Nazionale Applicazione Biotecnologie in Oncologia, Division of Urology, Regional Hospital, 30122, Venice, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Gion
authors.forename: R
authors.initials: R
authors.lastname: Mione
authors.forename: P
authors.initials: P
authors.lastname: Barioli
authors.forename: M
authors.initials: M
authors.lastname: Barichello
authors.forename: F
authors.initials: F
authors.lastname: Zattoni
authors.forename: T
authors.initials: T
authors.lastname: Prayer-Galetti
authors.forename: M
authors.initials: M
authors.lastname: Plebani
authors.forename: G
authors.initials: G
authors.lastname: Aimo
authors.forename: C
authors.initials: C
authors.lastname: Terrone
authors.forename: F
authors.initials: F
authors.lastname: Manferrari
authors.forename: G
authors.initials: G
authors.lastname: Madeddu
authors.forename: L
authors.initials: L
authors.lastname: Caberlotto
authors.forename: A
authors.initials: A
authors.lastname: Fandella
authors.forename: C
authors.initials: C
authors.lastname: Pianon
authors.forename: L
authors.initials: L
authors.lastname: Vianello
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001798:Blood Proteins / Q000378:metabolism; D003627:Data Interpretation, Statistical; D003937:Diagnosis, Differential; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D017430:Prostate-Specific Antigen / Q000097:blood*; D011470:Prostatic Hyperplasia / Q000097:blood / Q000175:diagnosis; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis*; D011485:Protein Binding; D011933:Reagent Kits, Diagnostic
chemical_list: D001798:Blood Proteins; D011933:Reagent Kits, Diagnostic; D017430:Prostate-Specific Antigen